An Unbiased View of pentobarbital sodium adverse effects
An Unbiased View of pentobarbital sodium adverse effects
Blog Article
Contraindicated (one)pentobarbital will minimize the level or effect of lumefantrine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with strong CYP3A4 inducers may result in diminished serum concentrations and lack of antimalarial efficacy
pentobarbital will decrease the level or effect of mavacamten by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will lower the extent or effect of paclitaxel by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unfamiliar.
pentobarbital will lessen the level or effect of fedratinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Effect of coadministering a strong CYP3A4 inducer with fedratinib hasn't been researched.
pentobarbital will lessen the level or effect of midostaurin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Potent CYP3A4 inducers may decrease midostaurin concentrations resulting in decreased efficacy.
Watch Closely (one)pentobarbital will lower the extent or effect of linagliptin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. Utilization of alternative remedies is strongly encouraged when linagliptin will be to be administered with a CYP3A4 inducer
Distinctive affected person populace: Dosage really should be decreased during the aged or debilitated simply because these people may be additional sensitive to barbiturates. Dosage click here should be diminished for individuals with impaired renal function or hepatic illness.
pentobarbital will lessen the level or effect of nelfinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Doxycycline: Phenobarbital continues to be demonstrated to shorten the half-life of doxycycline for so long as 2 weeks immediately after barbiturate therapy is discontinued.
pentobarbital will minimize the level or effect of ambrisentan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unknown.
pentobarbital will lower the level or effect of lonafarnib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib can be a delicate CYP3A4 substrate. Coadministration with potent or reasonable CYP3A4 inducers is contraindicated.
pentobarbital will minimize the level or effect of zonisamide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unknown.
pentobarbital will lower the level or effect of bosentan by affecting hepatic enzyme CYP2C9/ten metabolism. Slight/Significance Unidentified.
fentanyl transdermal and pentobarbital both equally maximize sedation. Steer clear of or Use Alternate Drug. Limit use to patients for whom alternative therapy choices are inadequate